Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 24:12:1811-1817.
doi: 10.2147/CIA.S142483. eCollection 2017.

Geroprotectors as a therapeutic strategy for COPD - where are we now?

Joanna Miłkowska-Dymanowska  1   2 , Adam J Białas  1   2 , Joanna Makowska  2   3 , Aleksandra Wardzynska  2   4 , Paweł Górski  1   2 , Wojciech J Piotrowski  1   2
Affiliations
Review

Geroprotectors as a therapeutic strategy for COPD - where are we now?

Joanna Miłkowska-Dymanowska et al. Clin Interv Aging. .

Abstract

Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality. There are still many gaps in knowledge about the cellular, molecular, and genetic mechanisms contributing to pathobiology of this disease. However, increasing evidence suggests that accelerated aging, chronic systemic inflammation, and oxidative stress play major roles in pathogenesis in COPD, thus opening new opportunities in therapy. Therefore, the aim of our review was to describe and discuss some of the most widely used therapeutics that affect the root cause of aging and oxidative stress (metformin, melatonin, sirolimus, statins, vitamin D, and testosterone) in context of COPD therapy.

Keywords: COPD; melatonin; metformin; statins; testosterone; vitamin D.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med. 2011;183(9):1129–1137. - PubMed
    1. Ito K, Mercado N. STOP accelerating lung aging for the treatment of COPD. Exp Gerontol. 2014;59:21–27. - PubMed
    1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. - PubMed
    1. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–180. - PubMed
    1. Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegte IGAT, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26(5):835–845. - PubMed

MeSH terms